Earlier this week, Sanofi Genzyme announced a clinical trial to test a drug designed for people with Parkinson’s disease (PD) who have a specific genetic mutation (GBA).
This study is a major step forward in PD research — it’s the first drug trial in which a person’s genetic status determines eligibility and is testing a potential therapy to slow or stop disease progression.
Read more on The Michael J. Fox Foundation’s blog:
First Trial Begins Testing Drug in People with GBA Mutation | Parkinson's Disease
Best, Debi